(+)-BORNEOL [464-43-7]

Minimum order 2

Cat# NB-64-30136-1mL

Size : 1mLx10mM(inDMSO)

Brand : Neo Biotech


(+)-BORNEOL (Synonyms: d-Borneol)

Catalog No. T5734 Copy Product Info
Purity: 99.6%
(+)-BORNEOL (d-Borneol) is a natural bicyclic monoterpene used for analgesia and anesthesia in traditional Chinese medicine; enhances GABA receptor activity with an EC50 of 248 μM.

(+)-BORNEOL

Copy Product Info
Synonyms d-Borneol

(+)-BORNEOL (d-Borneol) is a natural bicyclic monoterpene used for analgesia and anesthesia in traditional Chinese medicine; enhances GABA receptor activity with an EC50 of 248 μM.

(+)-BORNEOL
Cas No. 464-43-7
Select Batch
Purity:99.6%
Color:White
Contact us for more batch information

Product Introduction

Bioactivity
Description
(+)-BORNEOL (d-Borneol) is a natural bicyclic monoterpene used for analgesia and anesthesia in traditional Chinese medicine; enhances GABA receptor activity with an EC50 of 248 μM.
Targets&IC50
GABA:248 μM(EC50)
In vitro
Aβ-induced cell cytotoxicity was inhibited by 100 μM of (-) and (+) borneol treatment. Treatment of borneol significantly decreased ROS generation (P < 0.01). The expression of HO-1 and nuclear translocation of Nrf2 were increased by Aβ treatment. This nuclear translocation of Nrf2 was further increased by administration of borneol. Compared with the Aβ treated group, the (+) borneol treated group significantly increased Bcl-2 expression with decreased expression of Bax[1].
In vivo
(+)-borneol (1.0 mg/kg) significantly ameliorated infarct size and neurological scoresvia reducing the expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-alpha (TNF-α) in a dose dependent manner. Notably, (+)-borneol showed long-term effects on the improvement of sensorimotor functions in the photothrombotic model of stroke, which decreased the number of foot faults in the grid-walking task and forelimb asymmetry scores in the cylinder task, at least in part through reducing loss of dendritic spines in the length, brunch number and density. Suggest that (+)-borneol could serve as a therapeutic target for ischemic stroke[2].
Cell Research
Oxidative stress was induced by administering 50 μM Aβ into SH-SY5Y cells. Neuroprotective effect of commercially available borneol was examined by determining cell viability with the MTT assay. Intracellular reactive oxygen species (ROS) generation was measured using a fluorometer with further examination of heme oxygenase-1 (HO-1) and nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) expression. Apoptosis was examined by measuring the ratio of B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax)[1].
Animal Research
To mimic a typical human stroke, which does not undergo reperfusion, used a permanent MCAO in this study. For investigating the role of (+)-borneol in permanent cerebral ischemia, 45 male Sprague-Dawley rats were randomly divided into the sham group, the vehicle-treated group and the (+)-borneol-treated groups (1.0 mg/kg), with 15 rats in each group. The terminal half-life (t1/2) of borneol was 2 h following cerebral ischemia-reperfusion. We subjected the rats to pMCAO and administered drugs by tail intravenous injection 2 hours and 5 hours after pMCAO, respectively. The sham group and the vehicle-treated group were injected with vehicle administration. Neurologic scores were assessed at 48 hours after reperfusion[2].
Synonymsd-Borneol
Chemical Properties
Molecular Weight154.25
FormulaC10H18O
Cas No.464-43-7
SmilesCC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2
Relative Density.0.992g/cm3
Storage & Solubility Information
StorageShipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 247.5 mg/mL (1604.54 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (25.93 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM6.4830 mL32.4149 mL64.8298 mL324.1491 mL
5 mM1.2966 mL6.4830 mL12.9660 mL64.8298 mL
10 mM0.6483 mL3.2415 mL6.4830 mL32.4149 mL
20 mM0.3241 mL1.6207 mL3.2415 mL16.2075 mL
50 mM0.1297 mL0.6483 mL1.2966 mL6.4830 mL
100 mM0.0648 mL0.3241 mL0.6483 mL3.2415 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.